SEPTODONT HOLDINGS SAS – Trademark Portfolio

Entity Type: 99

SEPTODONT HOLDINGS SAS holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ORAVERSE. The owner is based in SAINT MAUR DES FOSSES.

58 RUE DU PONT DE CRETEIL

SAINT MAUR DES FOSSES 94100 , FR

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SEPTODONT HOLDINGS SAS's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does SEPTODONT HOLDINGS SAS have?

SEPTODONT HOLDINGS SAS has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 cancelled.

What trademark classes does SEPTODONT HOLDINGS SAS file in?

SEPTODONT HOLDINGS SAS files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SEPTODONT HOLDINGS SAS's most well-known trademarks?

SEPTODONT HOLDINGS SAS's registered trademark portfolio includes well-known marks such as ORAVERSE. These are among 1 currently registered trademark in the portfolio.

What is SEPTODONT HOLDINGS SAS's trademark registration success rate?

SEPTODONT HOLDINGS SAS has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.